Asset Details
Do you wish to reserve the book?
Effect of Adrenergic Agonists on High-Fat Diet-Induced Hepatic Steatosis in Mice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of Adrenergic Agonists on High-Fat Diet-Induced Hepatic Steatosis in Mice
Do you wish to request the book?
Effect of Adrenergic Agonists on High-Fat Diet-Induced Hepatic Steatosis in Mice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of Adrenergic Agonists on High-Fat Diet-Induced Hepatic Steatosis in Mice
2020
Overview
The autonomic nervous system, consisting of sympathetic and parasympathetic branches, plays an important role in regulating metabolic homeostasis. The sympathetic nervous system (SNS) regulates hepatic lipid metabolism by regulating adrenergic receptor activation, resulting in the stimulation of hepatic very-low-density lipoprotein-triglyceride (TG) production in vivo. However, only a few studies on the relationship between SNS and hepatic steatosis have been reported. Here, we investigate the effect of adrenergic receptor agonists on hepatic steatosis in mice fed a high-fat diet (HFD). The α-adrenergic receptor agonist phenylephrine (10 mg/kg/d) or the β-adrenergic receptor agonist isoproterenol (30 mg/kg/d) was coadministered with HFD to male mice. After five weeks, hepatic steatosis, TG levels, and hepatic fat metabolism-related biomarkers were examined. HFD treatment induced hepatic steatosis, and cotreatment with phenylephrine, but not isoproterenol, attenuated this effect. Phenylephrine administration upregulated the mRNA levels of hepatic peroxisome proliferator-activated receptor alpha and its target genes (such as carnitine palmitoyltransferase 1) and increased hepatic β-hydroxybutyrate levels. Additionally, phenylephrine treatment increased the expression of the autophagosomal marker LC3-II but decreased that of p62, which is selectively degraded during autophagy. These results indicate that phenylephrine inhibits hepatic steatosis through stimulation of β-oxidation and autophagy in the liver.
Publisher
MDPI AG,MDPI
Subject
3-Hydroxybutyric Acid - metabolism
/ Adrenergic alpha-1 Receptor Agonists - pharmacology
/ Adrenergic beta-Agonists - pharmacology
/ Agonists
/ Animals
/ Carnitine O-Palmitoyltransferase - genetics
/ Carnitine O-Palmitoyltransferase - metabolism
/ Diet, High-Fat - adverse effects
/ Isoproterenol - pharmacology
/ Male
/ Mice
/ Microtubule-Associated Proteins - genetics
/ Microtubule-Associated Proteins - metabolism
/ Phenylephrine - pharmacology
/ Proteins
